Drug intelligence / Profile preview

acevaltrate

Development stage
Preclinical
Lead developer
PharmaPrint
Modality
Small Molecules
Administration
Oral
01

Overview

Acevaltrate is a natural iridoid valepotriate isolated from plants of the *Valeriana* genus, including *Valeriana jatamansi* and *Valeriana glechomifolia*. It is being investigated as a multi-target antineoplastic agent with the ability to induce various forms of regulated cell death. Preclinical studies have demonstrated that acevaltrate induces ferroptosis in colorectal cancer cells by targeting the iron chaperones PCBP1/2 and the antioxidant enzyme GPX4. It also triggers pyroptosis in bortezomib-resistant multiple myeloma cells through a Caspase-3 and GSDME-dependent mechanism. Furthermore, acevaltrate has been shown to inhibit the accumulation of hypoxia-inducible factor-1α (HIF-1α) by suppressing its synthesis and promoting its degradation via the mTOR/p70S6K/4E-BP1 pathway. Additional research indicates its potential in glioblastoma by suppressing the USP10/CCND1 axis and in myeloma by inhibiting the Otub1/c-Maf axis. Preclinical models suggest it may overcome therapeutic resistance and exhibits a favorable safety profile compared to some first-line clinical drugs.

Other names
1-alpha-acevaltrate1-beta-acevaltrateAVT
02

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)PCBP1 (Poly(rC)-binding protein 1)OTUB1 (Ubiquitin carboxyl-terminal hydrolase OTUB1)HIF1A (Hypoxia-inducible factor 1-alpha)GPX4 (Glutathione peroxidase 4)

Beyond the preview

Go deeper on acevaltrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acevaltrate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call